These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Pemphigus foliaceus successfully treated with mycophenolate mofetil as a steroid-sparing agent. Katz KH; Marks JG; Helm KF J Am Acad Dermatol; 2000 Mar; 42(3):514-5. PubMed ID: 10688729 [TBL] [Abstract][Full Text] [Related]
11. Plasma and intracellular pharmacokinetic-pharmacodynamic analysis of mycophenolic acid in de novo kidney transplant patients. Thi MT; Mourad M; Capron A; Tshinanu FM; Vincent MF; Wallemacq P Clin Biochem; 2015 Apr; 48(6):401-5. PubMed ID: 25523299 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of inosine monophosphate dehydrogenase reduces adipogenesis and diet-induced obesity. Su H; Gunter JH; de Vries M; Connor T; Wanyonyi S; Newell FS; Segal D; Molero JC; Reizes O; Prins JB; Hutley LJ; Walder K; Whitehead JP Biochem Biophys Res Commun; 2009 Aug; 386(2):351-5. PubMed ID: 19523919 [TBL] [Abstract][Full Text] [Related]
13. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Sanquer S; Breil M; Baron C; Dhamane D; Astier A; Lang P Clin Pharmacol Ther; 1999 Jun; 65(6):640-8. PubMed ID: 10391669 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of inosine monophosphate dehydrogenase activity by the plasma of heart transplant recipients receiving mycophenolate mofetil. Griesmacher A; Weigel G; Seebacher G; Mallinger R; Laufer G; Müller MM Adv Exp Med Biol; 1998; 431():537-41. PubMed ID: 9598124 [No Abstract] [Full Text] [Related]
15. Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. Ahrens N; Salama A; Haas J J Neurol; 2001 Aug; 248(8):713-4. PubMed ID: 11569905 [No Abstract] [Full Text] [Related]
16. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation. Behrend M Clin Nephrol; 1996 May; 45(5):336-41. PubMed ID: 8738667 [TBL] [Abstract][Full Text] [Related]
17. [New trends in chemotherapy of systemic lupus erythematosus: treatment with mycophenolate mofetil]. Shekshina SV; Kliukvina NG; Nasonov EL; Nasonova VA Klin Med (Mosk); 2002; 80(4):26-30. PubMed ID: 12043258 [TBL] [Abstract][Full Text] [Related]
18. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment. Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785 [TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Allison AC; Eugui EM Immunol Rev; 1993 Dec; 136():5-28. PubMed ID: 7907572 [No Abstract] [Full Text] [Related]
20. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Takebe N; Cheng X; Wu S; Bauer K; Goloubeva OG; Fenton RG; Heyman M; Rapoport AP; Badros A; Shaughnessy J; Ross D; Meisenberg B; Tricot G Clin Cancer Res; 2004 Dec; 10(24):8301-8. PubMed ID: 15623606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]